As a result, an international multi-institutional research group in sub-Saharan Africa conducted one of the largest prospective clinical trials of new antimalarial drugs in recent years. This collaboration included the CANTAM network, the University of Tübingen as well as the non-profit company Medicines for Malaria Venture and the pharmaceutical company Shin Poong Pharmaceuticals. Prof. Michael Ramharter and Dr Mirjam Groger from the BNITM Clinical Research Department were responsible for the international coordination of the phase IIIb/IV clinical trial.
Between June 2017 and April 2019, more than 8,500 malaria episodes were enrolled in the study in five health centres in Cameroon, the Democratic Republic of Congo, Gabon, Côte d'Ivoire and the Republic of Congo. The study protocol was as close as possible to real-life clinical practice in the treatment of malaria and included young children, malnourished patients and patients with underlying diseases such as HIV or hepatitis.